Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan

[1]  J. Passweg,et al.  Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation , 2022, Bone Marrow Transplantation.

[2]  M. Krajinovic,et al.  GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation , 2021, Journal of Cancer Research and Clinical Oncology.

[3]  Patricia Huezo-Diaz Curtis,et al.  The analysis of GSTA1 promoter genetic and functional diversity of human populations , 2021, Scientific reports.

[4]  J. Passweg,et al.  Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial , 2020, Annals of Hematology.

[5]  M. Remberger,et al.  Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan‐Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation , 2019, Clinical and translational science.

[6]  S. Montoto,et al.  Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT , 2019, Bone Marrow Transplantation.

[7]  J. Oh,et al.  Effect of glutathione S‐transferase genetic polymorphisms on busulfan pharmacokinetics and veno‐occlusive disease in hematopoietic stem cell transplantation: A meta‐analysis , 2018, Basic & clinical pharmacology & toxicology.

[8]  Y. Daali,et al.  Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance , 2017, Therapeutic drug monitoring.

[9]  Patricia Huezo-Diaz Curtis,et al.  GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study , 2017, Oncotarget.

[10]  C. Hao,et al.  The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients. , 2015, Clinical immunology.

[11]  J. Oh,et al.  Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. , 2015, Pharmacogenomics.

[12]  J. Yin,et al.  Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients , 2015, Bone Marrow Transplantation.

[13]  M. MacMillan,et al.  Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. , 2015, Blood.

[14]  J. Pérez-Simón,et al.  Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  S. Bremer,et al.  Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning , 2014, Therapeutic drug monitoring.

[16]  M. Krajinovic,et al.  Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients , 2013, Bone Marrow Transplantation.

[17]  A. Gratwohl,et al.  Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT , 2011, Bone Marrow Transplantation.

[18]  S. Rodenhuis,et al.  Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide , 2008, Pharmacogenetics and genomics.

[19]  N. Kröger,et al.  Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. , 2007, Anticancer research.

[20]  Brian R. Phillips,et al.  Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  S. Park,et al.  Glutathione S‐transferase A1 polymorphisms and acute graft‐vs.‐host disease in HLA‐matched sibling allogeneic hematopoietic stem cell transplantation , 2007, Clinical transplantation.

[22]  J. Niland,et al.  Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  M. Edgren,et al.  The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo , 2002, Bone Marrow Transplantation.

[24]  M. Eichelbaum,et al.  Genetic polymorphisms of glutathione S‐transferase A1, the major glutathione S‐transferase in human liver: Consequences for enzyme expression and busulfan conjugation , 2002, Clinical pharmacology and therapeutics.

[25]  J. Wingard,et al.  Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  H. Deeg,et al.  Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. , 2001, Blood.

[27]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[28]  B. Andersson,et al.  Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  P. Ljungman,et al.  The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity , 2000, Bone Marrow Transplantation.

[30]  L. DeLeve,et al.  Role of Oxidative Stress and Glutathione in Busulfan Toxicity in Cultured Murine Hepatocytes , 2000, Pharmacology.

[31]  M. Hassan.  The role of busulfan in bone marrow transplantation , 1999, Medical oncology.

[32]  J. Slattery,et al.  Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. , 1998, Therapeutic drug monitoring.

[33]  J. Gibbs,et al.  Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[34]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .